Advertisement

Rezidivprophylaxe mit BCG versus Interferon-α beim oberflächlichen Harnblasenkarzinom

  • T. Kälble
  • G. Staehler
Conference paper

Zusammenfassung

BCG ist eine weltweit etablierte Substanz zur intravesikalen Rezidivprophylaxe des oberflächlichen Harnblasenkarzinoms sowie zur Therapie des Carcinoma in situ (Cis). Das Problem der BCG-Therapie besteht in der hohen Nebenwirkungsrate mit zystitischen Beschwerden und Fieber bis hin zur systemischen BCGitis mit Todesfolge (Deresiewicz et al. 1990; Lamm et al. 1986,1992b; Rawls et al. 1990) Das Wirkprinzip von BCG ist noch nicht in allen Einzelheiten geklärt, beruht jedoch u.a. auf einer Aktivierung des Immunsystems (Böhle et al. 1990a, b). Mit Interferon-α (IFN-α) steht ein Lymphokin zur Verfügung mit nachgewiesener in vitro- (Bahnson u. Ratliff 1988; Brouty-Boyé 1985; Grups u. Frohmüller 1988; Jakse et al. 1988; Rajala et al. 1992) und in vivo- (Bahnson u. Ratliff 1988; Borden et al. 1990) Aktivität gegenüber humanen und experimentellen Blasenkarzinomen. Insofern entschlossen wir uns zur Durchführung einer Studie zur Rezidivprophylaxe des oberflächlichen Urothelkarzinoms der Harnblase mit BCG versus IFN-α mit der Frage, ob IFN eine ähnlich gute rezidivprophylaktische Wirkung zeigt wie das BCG bei geringeren Nebenwirkungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bahnson R, Ratliff TL (1988) Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MRT-2) growth in vitro an in vivo. J Urol 140: 656–659PubMedGoogle Scholar
  2. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990a) Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53PubMedGoogle Scholar
  3. Böhle A, Nowc Ch, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990b) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette- Guerin immunotherapy. J Urol 144: 59PubMedGoogle Scholar
  4. Borden EC, Sidky YA, Ertürk E, Wierenga W, Bryan GT (1990) Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Cancer Res 50: 1071- 1074PubMedGoogle Scholar
  5. Brouty-Boye D, Mogensen KE, Gresser I (1985) Effects of long-term treatment of human carcinoma cells with interferon a. Eur J Cancer Clin Oncol 21: 507–514PubMedCrossRefGoogle Scholar
  6. Deresiewics RL, Stone RM, Aster JC (1990) Fatal disseminated mycobacterial infection following intravesical BCG. J Urol 144: 1331Google Scholar
  7. Ferrari P, Castagnetti G, Pollastri CA, Ferrari G, Tavoni F, Grassi D (1991) Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer, interferon alfa-2b versus interferon alfa-2b with epirubicin. Symposium „The current role of alpha-interferons in the treatment of bladder cancer”. Madrid, Spanien 02.02.91.Google Scholar
  8. Glashan RW (1990) A randomized controlled study of intravesical alfa-2b-inter- feron in carcinoma in situ of the bladder. J Urol 144: 658–661PubMedGoogle Scholar
  9. Grainger R, Donovan MG, Hegarty J, Butler MR, Fitzpatrick JM (1987) A prospective randomised study of intravesical BCG and interferon in superficial bladder cancer. 4th ECCO, Madrid, Spanien, 1.-4.11.87Google Scholar
  10. Grups JW, Frohmüller HGW, Ackermann R (1985) Immunological findings in patients with superficial bladder cancer during human alpha-2-interferon treatment. Urol Int 40: 301–306PubMedCrossRefGoogle Scholar
  11. Grups JW, Frohmüller HGW (1988) Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro. Urol Int 43: 265–268PubMedCrossRefGoogle Scholar
  12. Herr HW, Laudone VP, Badalament RA et al. (1988) Bacillus calmette-guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6: 1450PubMedGoogle Scholar
  13. Höltl W, Hasun R, Albrecht W (1991) Prospective randomized trial to evaluate high- versus low-dose interferon alpha 2b versus conventional chemotherapy in prevention of recurrence of superficial TU of the urinary bladder. Symposium „The current role of alpha interferone in the treatment of bladder cancers” Madrid, Spanien, 2.2.1991Google Scholar
  14. Ikic D, Nola P, Maricic Z et al. (1981). Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 9: 1022Google Scholar
  15. Jakse G, Marth C, Zechner J, Daxenbichel G (1988) Antiproliferative effect of hu-interferon-gamma in 674V and J82 bladder carcinoma cell lines. Urol Res 16: 403–405PubMedCrossRefGoogle Scholar
  16. Kälble T, Möhring K, Ikinger U, Riedasch G, Staehler G (1991) Intravesikale Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom mit BCG und KLH. Urologe A 30:118–121Google Scholar
  17. Kurth KH, Sylvester R, DePauw M, Ten Kate F (1989) Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience. Prog Clin Biol Res 310: 125PubMedGoogle Scholar
  18. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573–580PubMedGoogle Scholar
  19. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135: 272PubMedGoogle Scholar
  20. Lamm DL, Crawford ED, Blumenstein B et al. (1992a) Maintenance BCG immunotherapy of superfical bladder cancer: A randomized prospective southwest oncology group study. J Urol 147 (Suppl) 242Google Scholar
  21. Lamm DL, van der Meijden PM, Morales A et al. (1992b) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596–600PubMedGoogle Scholar
  22. Martinez-Pineiro JA, Jemenez LJ et al. (1990) Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized study in 202 patients with superficial bladder cancer. J Urol 143: 502PubMedGoogle Scholar
  23. Oliver RTD, Waxman JH, Kwok H, Fowler CG, Mathewman P, Blandy JP (1986) Alpha lymphoblastoid interferon for noninvasive bladder cancer. Br J Cancer 53: 432Google Scholar
  24. Ottesen SS, Ahrenkiel V, Kieler J (1990) Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A, B, C and DR in human urothelial cell lines. Cancer Immunol Immunother 31: 93–98PubMedCrossRefGoogle Scholar
  25. Pagano F, Bassi P, Milani C et al. (1991) Alow dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective? J Urol 146: 32PubMedGoogle Scholar
  26. Rajala P, Kaasinen E, Rintala E, Jauhiainen K, Nurmi M, Alfthan O, Lahde M (1992) Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and Interferon-alfa. Urol Res 20: 215–217PubMedCrossRefGoogle Scholar
  27. Rawls WH, Lamm DL, Lowe BA et al. (1990) Fatal sepsis following intravesical BCG administration for bladder cancer. J Urol 144: 1328PubMedGoogle Scholar
  28. Rubben H, Lutzeyer W, Fischer N, Deutz FJ, Lagrance W, Giani G and members of the Registry for Urinary Tract Tumors (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139: 283Google Scholar
  29. Sarosdy MF, Kierum CA (1989) Combination immunotherapy of murine transitional cell cancer using BCG and an interferon inducing pyrimidinone. J Urol 142: 1376–1379PubMedGoogle Scholar
  30. Williams RD (1988) Intravesical interferon alfa in the treatment of superficial bladder cancer. Seminars in Oncology 15 (Suppl 5): 10–13PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • T. Kälble
  • G. Staehler
    • 1
  1. 1.Abteilung UrologieChirurgische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations